DECLARATIONS Acknowledgments The authors thank Professor Manuela Simoni for her precious scientific support
Liu D, Liu Y, Ran L, Shang H, Li D
Body weight, median (IQR), remained stable during the study period (65.8 kg [55.377.5] and 65.3 kg [56.5-78.5] for dulaglutide and placebo, respectively)
The message is clear: Compounding and dispensing essentially a copy of commercially available semaglutide or tirzepatide without medical necessity violates the Food, Drug, and Cosmetic Act (FD&C Act) and can result in legal action
You will never feel rushed during
Based on extensive stability testing under controlled conditions